Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.
Novo Nordisk (NVO) has been granted an exclusive worldwide license to Ascendis Pharma’s (ASND) TransCon technology platform to develop its proprietary products in metabolic and cardiovascular diseases ...
Some results have been hidden because they may be inaccessible to you